<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23794" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Itraconazole</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kurn</surname>
            <given-names>Heidi</given-names>
          </name>
          <aff>Midwestern University - CCOM</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wadhwa</surname>
            <given-names>Roopma</given-names>
          </name>
          <aff>South Carolina Department of Mental Health</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Heidi Kurn declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Roopma Wadhwa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23794.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Itraconazole is a medication used in the management and treatment of fungal infections. It is in the antifungal class of drugs. Many of these fungal infections are rare; however, they can be detrimental to the immunocompromised. Some patient populations that frequently use itraconazole prophylaxis are patients with HIV, those receiving chemotherapy, or people who have had an organ transplant. This activity reviews the indications, mechanism of action, adverse event profile, and contraindications for itraconazole as a valuable agent in treating systemic fungal infections and other disorders, including off-label indications pertinent for healthcare team members in the treatment of patients with systemic fungal infections and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of itraconazole.</p></list-item><list-item><p>Describe the potential adverse effects of itraconazole.</p></list-item><list-item><p>Review the appropriate monitoring of patients using itraconazole.</p></list-item><list-item><p>Summarize some interprofessional team strategies for improving care coordination and communication to advance itraconazole and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23794&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23794">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23794.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Itraconazole can treat many different fungal infections. Many of these fungal infections are rare; however, they can be detrimental to the immunocompromised. Itraconazole (sometimes abbreviated ITZ) treats blastomycosis, histoplasmosis, and aspergillosis and has FDA approval as a treatment for these infections. However, itraconazole has also shown efficacy in treating paracoccidioidomycosis, coccidioidomycosis, and candidiasis, but it does not have FDA approval for these conditions.<xref ref-type="bibr" rid="article-23794.r1">[1]</xref><xref ref-type="bibr" rid="article-23794.r2">[2]</xref>&#x000a0;In addition to treating infections, itraconazole can be used as prophylaxis in patients at risk of these systemic fungal infections. Some patient populations that frequently use itraconazole prophylaxis are patients with HIV, those receiving chemotherapy, or people who have had an organ transplant. Itraconazole offers excellent prophylaxis for these immunocompromised patients due to its broad-spectrum coverage, safety profile, and minimal fungal resistance.<xref ref-type="bibr" rid="article-23794.r3">[3]</xref></p>
        <p>In addition to treating systemic infections, itraconazole can also treat superficial fungal infections like onychomycosis, which has FDA approval. However, the cure rate of onychomycosis with itraconazole therapy is only 63%.<xref ref-type="bibr" rid="article-23794.r4">[4]</xref> Itraconazole can also treat moderate to severe seborrheic dermatitis and other topical mycoses, although this use does not have FDA approval. Although itraconazole is an effective therapy for seborrheic dermatitis, antifungal shampoos and topical steroids are first-line therapies. When treating seborrheic dermatitis, itraconazole administration occurs as a pulse therapy, which means large doses of the drug are administered intermittently to avoid side effects but achieve the drug&#x02019;s therapeutic effects.<xref ref-type="bibr" rid="article-23794.r5">[5]</xref></p>
      </sec>
      <sec id="article-23794.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Itraconazole is a broad-spectrum antifungal agent; it has an active metabolite; hydroxyitraconazole. Itraconazole inhibits ergosterol synthesis, which helps maintain the cell membrane in fungi. Lanosterol must undergo a 14 alpha-demethylation reaction to become ergosterol, which is catalyzed by fungal&#x000a0;14 alpha-demethylase. Itraconazole blocks this reaction by interacting with the fungal&#x000a0;14 alpha-demethylase substrate-binding site. This impaired ergosterol synthesis leads to fungal membrane abnormalities that increase permeability and disrupt fungal cell membrane integrity,&#x000a0;changing membrane-bound enzyme activity.<xref ref-type="bibr" rid="article-23794.r6">[6]</xref></p>
        <p>The drug is metabolized extensively via the CYP450 system; specifically, itraconazole is a CYP3A4 substrate. It has a half-life of 34 to 42 hours. The drug is excreted in the urine (35%) feces (between 3 and 18%).</p>
      </sec>
      <sec id="article-23794.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Itraconazole can be administered intravenously (10 mg/mL), in a capsule (100 mg), or as an oral solution (10 mg/mL) that allows administering the drug in the inpatient or outpatient setting. The absorption of the itraconazole via the capsule is highly variable&#x02014;this variability results from intestinal epithelial damage and varying gastric acid environments from person to person. However, the newer formulations of the drug, intravenous and oral solutions, which contain hydroxypropyl-beta-cyclodextrin, have shown better absorption and bioavailability.<xref ref-type="bibr" rid="article-23794.r1">[1]</xref><xref ref-type="bibr" rid="article-23794.r3">[3]</xref></p>
        <p>Dosing by indication (FDA-approved) is as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Onychomycosis of the Fingernails</bold>
<list list-type="bullet"><list-item><p>200 mg orally twice daily (capsules) for seven days, followed by 21 days off. Give two courses for immunocompromised patients.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Fungal Infections</bold>&#x000a0;
<list list-type="bullet"><list-item><p>200 mg by mouth daily or twice daily (capsules); start 200 mg twice daily for three days in life-threatening infections. The maximum dose is 600 mg daily. Divide doses over 200 mg daily; give with food.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Onychomycosis of the Toenails</bold>
<list list-type="bullet"><list-item><p>200 mg orally (capsules) each day for 12 weeks</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Candidiasis</bold>
<list list-type="bullet"><list-item><p>Oropharyngeal: 20 mL orally for one to two weeks; swish and swallow. Alternately, dose 10 mL orally twice daily for 2 to 4 weeks.</p></list-item><list-item><p>Esophageal: 20 mL orally twice daily for 14 to&#x000a0;21&#x000a0;days.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Blastomycosis</bold>
<list list-type="bullet"><list-item><p>200 mg orally daily (capsules); maximum dose 400 mg per day. Pulmonary and extrapulmonary disease can increase dosing by 100 mg increments if there is no therapeutic response; divide doses above 200 mg daily. The maximum dose is 600 mg daily.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Histoplasmosis</bold>
<list list-type="bullet"><list-item><p>200 mg orally daily (capsules), maximum dosage of 400 mg per day. Can increase dosing by 100&#x000a0;mg increments if there is no therapeutic response; divide doses above 200 mg daily.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Invasive Aspergillosis</bold>
<list list-type="bullet"><list-item><p>20 mL orally every 12 hours; alternatively, 200 to 400 mg daily (capsules) - give the patient the oral solution without food and the capsules with food;&#x000a0;divide doses above 200 mg daily.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Off-label indications and dosing:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Mycoses, superficial:</bold> 100 mg orally daily or twice daily Maximum dose 600 mg per day; divide doses above 200 mg.</p>
          </list-item>
          <list-item>
            <p><bold>Coccidioidomycosis:</bold> 200 mg every 12 hours.</p>
          </list-item>
          <list-item>
            <p><bold>Cutaneous or lymphocutaneous sporotrichosis:</bold> 200 mg daily by mouth; can be increased to 200 mg twice daily - continue therapy until two to four weeks after the resolution of lesions. The oral solution preparation is preferable.</p>
          </list-item>
        </list>
        <p>The capsules and the oral solution are not bioequivalent; the oral solution has higher bioavailability, so caution is advised when switching between formulations.</p>
        <p>Renal dosing: CrCl under 10; reduce dose by 50%. In peritoneal and hemodialysis patients, dosing is 100 mg every 12 to 24 hours, with no supplement.</p>
        <p>Hepatic dosing is undefined, but clinicians should exercise caution.</p>
      </sec>
      <sec id="article-23794.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>While itraconazole is a relatively safe medication, there are some adverse side effects with itraconazole use. Cardiotoxicity is a rare adverse effect. Itraconazole can decrease heart contractility and left ventricular ejection fraction.<xref ref-type="bibr" rid="article-23794.r7">[7]</xref> The risk of cardiotoxicity increases with a dose greater than 400 mg/day. While most patients' heart function improves after discontinuing itraconazole, some require a transplant.<xref ref-type="bibr" rid="article-23794.r8">[8]</xref></p>
        <p>Another adverse effect is hepatotoxicity, which is often a reversible increase in aminotransferase levels. This side effect is minimizable with intermittent or short-term dosing. In patients already being treated for hypertension, itraconazole can cause resistant hypertension.<xref ref-type="bibr" rid="article-23794.r9">[9]</xref></p>
        <p>The most common adverse effects are gastrointestinal disturbances, such as nausea, mild diarrhea, vomiting, and abdominal pain. Researchers noted these side effects in 2 to 39% of patients that have used itraconazole.<xref ref-type="bibr" rid="article-23794.r2">[2]</xref> When itraconazole administration is via the intravenous formulation, there is also a risk of injection site reactions, headache, and rash.</p>
      </sec>
      <sec id="article-23794.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are some contraindications for itraconazole use. The main one is heart failure or a history of heart failure due to itraconazole&#x02019;s potential cardiotoxic effects. Another contraindication is liver failure or disease because itraconazole can cause hepatotoxicity. Itraconazole is also contraindicated in pregnant patients. It has demonstrated teratogenic and embryotoxic effects in animal studies. Researchers found itraconazole to cause eye defects in babies whose mothers had exposure to the drug during pregnancy in a systematic review.<xref ref-type="bibr" rid="article-23794.r10">[10]</xref></p>
        <p>Itraconazole also has the potential for many drug-drug interactions because it is metabolized by cytochrome P450 (specifically CYP3A4) in the liver, like many other drugs. For example, patients taking itraconazole and terfenadine, astemizole, or cisapride may have serious cardiac rhythm disturbances. Itraconazole can also prolong the sedative effects of medications such as midazolam and triazolam, which means clinicians should avoid this combination. Itraconazole can also enhance the effects of oral antidiabetic drugs, which can result in severe hypoglycemia. It is essential to consider drug-drug interactions when prescribing itraconazole, especially if the same cytochrome enzyme metabolizes the other drugs in the liver.<xref ref-type="bibr" rid="article-23794.r2">[2]</xref></p>
      </sec>
      <sec id="article-23794.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Itraconazole should have a trough concentration of 0.5&#x000a0;to 1.0 mg/L to treat and prevent fungal infections. Trough concentration is the drug&#x02019;s lowest concentration immediately prior to the next dose.<xref ref-type="bibr" rid="article-23794.r11">[11]</xref> Itraconazole typically requires a prolonged maintenance treatment period, so patients should see their physician regularly to ensure that no adverse effects are developing. The concentration of itraconazole should be checked after a week of use and at regular intervals afterward. The drug concentration requires monitoring if the dose of itraconazole changes or if the prescriber adds a medication to a patient&#x02019;s regimen metabolized by the same liver enzyme as itraconazole.</p>
        <p>Regular monitoring can be useful to exclude issues with unanticipated changes in pharmacokinetics or problems with compliance. In addition to monitoring the drug concentration, patients should also have their liver enzymes checked regularly to ensure no hepatotoxicity.<xref ref-type="bibr" rid="article-23794.r2">[2]</xref>&#x000a0;LFTs should be taken at baseline and checked periodically in patients with hepatic impairment or if treatment extends past one month.</p>
      </sec>
      <sec id="article-23794.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxic trough levels for itraconazole are over 3 mcg/mL.<xref ref-type="bibr" rid="article-23794.r12">[12]</xref>&#x000a0;There is no specific antidote available.</p>
      </sec>
      <sec id="article-23794.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing antifungal prophylaxis in immunocompromised patients requires the entire interprofessional healthcare team, including clinicians (MDs, DOs, PAs, NPs), infectious disease specialists in severe cases, nursing staff, pharmacists, and laboratory technologists. If itraconazole therapy is not adequately managed, patients are likely to contract life-threatening fungal infections or experience adverse side effects. Whether these patients are immunocompromised due to HIV, chemotherapy, or organ transplant, drugs like itraconazole can be lifesaving.<xref ref-type="bibr" rid="article-23794.r1">[1]</xref> When an immunocompromised patient presents to the hospital, the physician and assigned nurse are responsible for coordinating care. This includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Assessing the patient for any signs of current fungal infections</p>
          </list-item>
          <list-item>
            <p>Reviewing the patient&#x02019;s cardiac history. If the patient has any history of arrhythmias or heart failure, consult cardiology.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ordering liver enzymes to evaluate the liver&#x02019;s function.<xref ref-type="bibr" rid="article-23794.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Consult with an infectious disease physician to ensure that itraconazole will provide adequate coverage for the patient.</p>
          </list-item>
          <list-item>
            <p>Consult with the pharmacist to ensure no drug-drug interactions exist between itraconazole and the patient&#x02019;s current medication; in severe cases, an infectious disease specialty pharmacist can be a valuable addition to the interprofessional team.</p>
          </list-item>
        </list>
        <p>The management of itraconazole prophylaxis does not stop after the initial visit and therefore requires the efforts of an interprofessional healthcare team, including clinicians, infectious disease specialists, nursing staff, pharmacists, and other healthcare personnel. Following ordering/prescribing and administration of the drug, itraconazole levels require regular monitoring, and the patients require monitoring for the development of any adverse reactions. These patients may also benefit from a mental health counselor; many of these patients are very sick, which can take a toll on their mental health. Furthermore, social workers should be involved in the care of these patients. Many immunocompromised patients use many costly medications, which can be a burden. Social workers can help get drugs covered or find other ways to assist these patients financially. Only by working together can an interprofessional team provide safe and effective itraconazole prophylaxis in immunocompromised patients. [Level 5]</p>
      </sec>
      <sec id="article-23794.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23794&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23794">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23794/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23794">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23794.s11">
        <title>References</title>
        <ref id="article-23794.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boogaerts</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maertens</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical experience with itraconazole in systemic fungal infections.</article-title>
            <source>Drugs</source>
            <year>2001</year>
            <volume>61 Suppl 1</volume>
            <fpage>39</fpage>
            <page-range>39-47</page-range>
            <pub-id pub-id-type="pmid">11219549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23794.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pi&#x000e9;rard</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Arrese</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Pi&#x000e9;rard-Franchimont</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Itraconazole.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>287</fpage>
            <page-range>287-304</page-range>
            <pub-id pub-id-type="pmid">11249550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23794.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willems</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>van der Geest</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Beule</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics.</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>159</fpage>
            <page-range>159-69</page-range>
            <pub-id pub-id-type="pmid">11422598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23794.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Westerberg</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Voyack</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Onychomycosis: Current trends in diagnosis and treatment.</article-title>
            <source>Am Fam Physician</source>
            <year>2013</year>
            <month>Dec</month>
            <day>01</day>
            <volume>88</volume>
            <issue>11</issue>
            <fpage>762</fpage>
            <page-range>762-70</page-range>
            <pub-id pub-id-type="pmid">24364524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23794.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paquet</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of oral treatments for seborrheic dermatitis.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <page-range>16-26</page-range>
            <pub-id pub-id-type="pmid">23802806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23794.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Beule</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Van Gestel</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of itraconazole.</article-title>
            <source>Drugs</source>
            <year>2001</year>
            <volume>61 Suppl 1</volume>
            <fpage>27</fpage>
            <page-range>27-37</page-range>
            <pub-id pub-id-type="pmid">11219548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23794.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abraham</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Panda</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Itraconazole Induced Congestive Heart Failure, A Case Study.</article-title>
            <source>Curr Drug Saf</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-61</page-range>
            <pub-id pub-id-type="pmid">28971777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23794.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paul</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rawal</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Cardiotoxicity with Itraconazole.</article-title>
            <source>BMJ Case Rep</source>
            <year>2017</year>
            <month>Apr</month>
            <day>10</day>
            <volume>2017</volume>
            <pub-id pub-id-type="pmid">28400399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23794.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Denolle</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Azizi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Massart</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zennaro</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>[Itraconazole: a new drug-related cause of hypertension].</article-title>
            <source>Ann Cardiol Angeiol (Paris)</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>213</fpage>
            <page-range>213-5</page-range>
            <pub-id pub-id-type="pmid">24952675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23794.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Fetal outcomes after maternal exposure to oral antifungal agents during pregnancy: A systematic review and meta-analysis.</article-title>
            <source>Int J Gynaecol Obstet</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>148</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-13</page-range>
            <pub-id pub-id-type="pmid">31691277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23794.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashbee</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gorton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2014</year>
            <month>May</month>
            <volume>69</volume>
            <issue>5</issue>
            <fpage>1162</fpage>
            <page-range>1162-76</page-range>
            <pub-id pub-id-type="pmid">24379304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23794.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kably</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Launay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Derobertmasure</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lefeuvre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dannaoui</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Billaud</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Antifungal Drugs TDM: Trends and Update.</article-title>
            <source>Ther Drug Monit</source>
            <year>2022</year>
            <month>Feb</month>
            <day>01</day>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>166</fpage>
            <page-range>166-197</page-range>
            <pub-id pub-id-type="pmid">34923544</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
